We are developing first-in-class precision medicines as disease modifying treatments for severe neurological disorders including epileptic conditions and Parkinson’s disease. Our rapidly advancing pipeline begins with genetically validated targets and promises broad therapeutic potential, with a chance to slow the progression of these devastating early childhood syndromes and adult neurological disorders.
Targeting severe developmental & epileptic encephalopathies and neurodegenerative disorders
First-in-class precision medicines for disease modifying treatments in severe neurological disorders including epileptic conditions and Parkinson’s disease. Rapidly advancing a pipeline of genetically validated programs towards the clinic.